Oak Ridge, NC, United States of America

Jielin Sun

This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: Wake Forest University. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jielin Sun. Retrieved from https://idiyas.com/inventor/jielin-sun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jielin Sun’s Patents in Genetic Risk Assessment

Introduction

Jielin Sun is an inventor associated with Wake Forest University and based in Oak Ridge, North Carolina. Her listed patent portfolio includes 3 patents, with work focused on methods for assessing genetic risk related to prostate cancer.

Latest Patents

One of Sun’s listed inventions is “Methods and Compositions for Correlating Genetic Markers with Prostate Cancer Risk.” The invention describes analyzing a subject’s nucleic acid sample to determine genotypes at multiple biallelic polymorphic loci, then using those results to calculate a cumulative relative risk (CRR). A CRR greater than 1.00 may indicate increased prostate cancer risk and help identify individuals who could be candidates for early PSA screening, prostate biopsy, or chemoprevention.

Career Highlights

Sun’s listed patent work connects genetic-marker analysis with risk assessment, aiming to translate genotype information into a cumulative measure that may inform clinical decisions. The supplied information identifies Wake Forest University as her affiliated organization.

Collaborations

The supplied information names Andrew Karim Kader and Jianfeng Xu as Sun’s coworkers. It does not specify their roles in the patent or the extent of their collaboration.

Conclusion

Jielin Sun’s listed invention applies genetic-marker analysis to prostate cancer risk assessment, with potential relevance to screening and other preventive care decisions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…